HomeCompareHLOC vs JNJ

HLOC vs JNJ: Dividend Comparison 2026

HLOC yields 425.53% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HLOC wins by $18058.56M in total portfolio value
10 years
HLOC
HLOC
● Live price
425.53%
Share price
$0.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18058.60M
Annual income
$12,349,610,253.13
Full HLOC calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — HLOC vs JNJ

📍 HLOC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHLOCJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HLOC + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HLOC pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HLOC
Annual income on $10K today (after 15% tax)
$36,170.21/yr
After 10yr DRIP, annual income (after tax)
$10,497,168,715.16/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, HLOC beats the other by $10,497,164,729.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HLOC + JNJ for your $10,000?

HLOC: 50%JNJ: 50%
100% JNJ50/50100% HLOC
Portfolio after 10yr
$9029.31M
Annual income
$6,174,807,471.26/yr
Blended yield
68.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

HLOC
No analyst data
Altman Z
10.0
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HLOC buys
0
JNJ buys
0
No recent congressional trades found for HLOC or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHLOCJNJ
Forward yield425.53%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$18058.60M$30.3K
Annual income after 10y$12,349,610,253.13$4,689.40
Total dividends collected$17541.95M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HLOC vs JNJ ($10,000, DRIP)

YearHLOC PortfolioHLOC Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$53,253$42,553.19$10,592$272.30+$42.7KHLOC
2$268,765$211,784.42$11,289$357.73+$257.5KHLOC
3$1,286,515$998,936.38$12,123$472.89+$1.27MHLOC
4$5,845,421$4,468,849.76$13,141$629.86+$5.83MHLOC
5$25,230,957$18,976,356.52$14,408$846.81+$25.22MHLOC
6$103,547,438$76,550,313.71$16,021$1,151.60+$103.53MHLOC
7$404,404,397$293,608,638.27$18,122$1,588.22+$404.39MHLOC
8$1,504,383,912$1,071,671,207.21$20,930$2,228.20+$1504.36MHLOC
9$5,335,499,864$3,725,809,078.26$24,792$3,191.91+$5335.48MHLOC
10$18,058,595,107$12,349,610,253.13$30,274$4,689.40+$18058.56MHLOC

HLOC vs JNJ: Complete Analysis 2026

HLOCStock

Helo Corp., a wellness technology company, provides wearable devices for use in the quantified-self wellness market. The company's wearable devices and related applications offer its end-users with health-related knowledge acquired through self-tracking. It offers VYYO Vista, which captures data that can be used to analyze resting and exercising heart rates, blood pressure estimation, breath rate, and energy levels, as well as provide insights into mood and sleep; and VYVO Sense, a smartband with 6 axes movement detection and an electrocardiogram (ECG) sensor. The company also provides VYVO Icon, a smartwatch that enables data to be collected to allow third parties to deduce parameters, such as body fat percentage, visceral fat levels, muscle, and bone mass; gather data to generate a third-party representation of an ECG; and provide continuous detection of possible irregular heartbeats comprising an atrial fibrillation or other arrhythmias. In addition, it offers VYVO Leggera, a smart weighing scale that can measure body weight, and has a BI sensor to capture data used to deduce bone weight, visceral fat, and body mass index; VYVO Vista+; and VYVO Watch Lite, which has data collection capabilities that enable features, including continuous atrial fibrillation detection, mood, and energy monitoring, as well as fall detection, SpO2 measurement capability, and sleep apnea detection. Further, it provides VYVO Watch Lite SE, which offers a body temperature result with an accuracy of up to ±0.1°C; and VYVO Watch Generation 2, a watch that enables medical-grade measurements with enhanced data accuracy for blood oxygen measurements, vascular aging, and ECGs. Helo Corp. sells its products through its marketing and distribution partner, VYVO HK Ltd., and its distribution network. The company was formerly known as World Technology Corp. and changed its name to Helo Corp. in October 2018. Helo Corp. was incorporated in 2010 and is headquartered in San Francisco, California.

Full HLOC Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this HLOC vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HLOC vs SCHDHLOC vs JEPIHLOC vs OHLOC vs KOHLOC vs MAINHLOC vs ABBVHLOC vs MRKHLOC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.